Picture supply: Getty Photos
It has been a protracted whereas since I noticed penny share Creo Medical (LSE:CREO) prime the FTSE AIM All-Share Index. However that’s certainly what occurred earlier at present (22 Might) when the inventory jumped 29% to 15p.
Let’s take a more in-depth take a look at what brought on this sudden spike, and whether or not Creo is likely to be value contemplating.
What does it do?
For these unfamiliar, Creo is a medical gadget firm that specialises within the area of minimally invasive surgical endoscopy, with a robust deal with treating pre-cancer and most cancers sufferers.
Put merely, the small-cap agency’s expertise permits medical doctors to carry out advanced procedures contained in the physique utilizing versatile tubes (endoscopes). Its core innovation is a sophisticated vitality platform that mixes two kinds of vitality via a single connection.
For the file, I personal a small place within the inventory, and it’s even smaller at present after dropping 50% up to now two years. Partly it’s because buyers have soured on unprofitable small caps like Creo as rates of interest have stayed larger for longer.
Why’s Creo taking off like a speedboat?
There are three issues which have despatched the inventory surging at present. Firstly, Creo raised £5.5m by putting 36.7m new shares at 15p every. Crucially, this represented an enormous premium to the day before today’s closing inventory value.
Firm administrators additionally personally put up £2.15m of this quantity, signalling sturdy confidence within the agency’s industrial potential. They’d know higher than anybody else, in any case.
Second, the agency introduced a non-binding settlement to promote its remaining 49% stake in Creo Medical Europe (a provider of third-party medical units and consumables). It received £24.7m for promoting the opposite 51% final yr.
Lastly, the corporate delivered sturdy outcomes for 2025. Income jumped 50% to £6m, with momentum constructing within the second half.
The underlying working loss decreased by 38.5% to £13.7m, which administration put right down to revenues scaling “in opposition to a considerably decrease price base“.
The great momentum continued into the beginning of 2026, with income growing round 60% within the first quarter. This gave administration the boldness to lift full-year income progress steering to 50%-60% (up from 40%-60%).
We exited 2025 with sturdy operational and industrial momentum, pushed by the validation of our core product vary, progress throughout our pipeline of latest units and growing scientific adoption.
CEO Craig Gulliford
Price a glance?
Earlier than at present, analysts have been anticipating 2026 income of £9.23m, with losses progressively narrowing over the subsequent three years. The excellent news is that Creo ought to have fairly a bit of money on the stability sheet shifting ahead, permitting it to deal with getting extra hospitals to undertake its medical instruments.
Talking of which, its SpydrBlade Flex gadget has been permitted, becoming a member of its flagship Speedboat product. The latter is already getting used commercially in main world markets, displaying sturdy progress in higher gastrointestinal procedures.
Is the inventory value contemplating? Effectively, it’s actually excessive danger as a result of lack of income. However a market cap of £61m offers the inventory a forward-looking price-to-sales ratio of round 6, which isn’t excessive for a fast-growing firm.
With the inventory nonetheless down 50% from two years in the past, at present’s run might need legs, making it value a search for risk-takers. Me? I’m going to maintain holding as a result of I believe it can recuperate in time.
Do you have to make investments £5,000 in Creo Medical Group Plc proper now?
When investing knowledgeable Mark Rogers and his staff have a inventory tip, it could actually pay to hear. In any case, the flagship Twelfth Magpie Share Advisor publication he has run for almost a decade has offered hundreds of paying members with prime inventory suggestions from the UK and US markets.
And proper now, Mark thinks there are 6 standout shares that buyers ought to contemplate shopping for. Wish to see if Creo Medical Group Plc made the listing?
Ben McPoland owns shares in Creo Medical.
